NovaBay Pharmaceuticals, Inc.
NBYStock
$1.22−66.19%52W
Market Cap$51.92M
P/E—
Div yield0.00%
Beta0.06
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-105.47%
Price vs S&P 500 (4W)14.84%
VGM Score25.72
Market Capitalization$51.92M
Indicated Dividend Yield (Annual)0.00%
Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NBYNovaBay Pharmaceuticals, Inc. | D | D | F | $1.22 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
NovaBay Pharmaceuticals develops and commercializes clinically-proven eyecare, wound care, and skin care products. Its flagship product, Avenova Antimicrobial Lid and Lash Solution, is marketed directly to consumers online and prescribed by eyecare professionals for blepharitis and dry-eye disease. The product features broad-spectrum antimicrobial properties to remove microorganisms and debris from the eye area.